Last updated: July 28, 2025
Introduction
Japan’s patent JP2014114320, titled “Method for Producing a Pharmaceutical Composition with Enhanced Bioavailability,” exemplifies innovation in drug formulation and delivery. Its significance lies in its claims that potentially cover novel manufacturing processes or composition enhancements aimed at optimizing bioavailability of active pharmaceutical ingredients (APIs). This analysis delves into the patent’s scope, claims, and the broader patent landscape, providing clarity on its strategic implications for stakeholders within the pharmaceutical industry.
Patent Overview
JP2014114320 was published on June 12, 2014. The patent application was filed by a leading Japanese pharmaceutical company and pertains to pharmaceutical formulations designed to improve drug bioavailability. The patent’s teachings revolve around a specific method of manufacturing or formulating drugs that result in enhanced absorption or bioavailability, key parameters in efficacy and patient compliance.
Scope of Patent JP2014114320
The scope of JP2014114320 primarily encompasses the methodology of producing a pharmaceutical composition that demonstrates improved bioavailability. The scope extends to:
- Process Claims: Detailing technical steps like specific manufacturing conditions, excipient combinations, or particle size modifications.
- Composition Claims: Covering specific drug formulations with particular excipients, carriers, or physical characteristics such as particle size, crystalline form, or coating.
- Application of Techniques: Using particular processing techniques (e.g., micronization, spray-drying, or melt extrusion) to achieve desired bioavailability improvements.
The patent emphasizes that the claimed methods or compositions result in improved pharmacokinetic parameters—such as increased plasma concentration (Cmax), extended half-life (T½), or enhanced absorption rate—over conventional counterparts.
Claims Analysis
The claims are the core legal protections of the patent, and their scope directly influences patent enforceability and infringement potential.
Independent Claims
The independent claims generally cover:
- A method of producing a pharmaceutical composition involving specific steps, such as:
- Particular particle size reduction techniques (e.g., micronization or nanonization).
- Unique processing conditions (e.g., temperature, humidity, or solvent conditions).
- Combination of excipients that stabilize or facilitate absorption.
- A pharmaceutical composition comprising:
- An active ingredient with certain physical characteristics, such as amorphous or crystalline form.
- Specific excipients or delivery systems (e.g., lipid-based carriers, nanoparticles).
- A certain physicochemical profile associated with enhanced bioavailability.
Dependent Claims
Dependent claims narrow the scope further, specifying embodiments such as:
- Specific active pharmaceutical ingredients (e.g., a particular API like a BCS class II drug).
- Particular excipient combinations (e.g., surfactants, polymers).
- Specific physical forms, like spray-dried powders or freeze-dried complexes.
- Particular dosing forms, such as tablets, capsules, or suspensions.
Claim Scope
The claims focus on both method and composition, which characterizes the patent as a nuanced approach to bioavailability enhancement rather than a mere formulation. The breadth of method claims is noteworthy, as they could potentially cover a wide range of processes used to produce such formulations, provided they meet the structural elements set forth.
Patent Landscape
The patent landscape surrounding JP2014114320 reveals significant activity in the area of bioavailability enhancement and pharmaceutical formulation methods in Japan and globally. Key insights include:
1. Related Patents and Prior Art
The patent references prior art that includes:
- Techniques for micronization and nanonization of APIs.
- Formulation strategies involving lipid-based carriers to improve solubility.
- Solid-state modifications (e.g., amorphous forms, salts) to optimize absorption.
Notable prior art includes U.S. and European patents focusing on nanocrystal technologies and lipid-based formulations, indicating that JP2014114320 builds upon established foundational techniques while aiming to carve out specific inventive space.
2. Patent Families and International Protection
This patent forms part of a broader patent family with equivalents filed in key jurisdictions like the US and Europe, indicating an intent for international protection. The family members likely claim similar processes or formulations, synchronizing patent rights across markets where drug development and commercialization are pursued.
3. Competitive and Collaborative Landscape
Several pharmaceutical companies and biotech firms are actively patenting bioavailability-enhancing technologies. This landscape reflects advanced R&D investments focused on optimizing existing APIs and developing innovative delivery systems, often involving nanotechnology and lipid-based approaches.
4. Patent Trends and Issuances
Recent trends reveal increased filings in Japan, China, and the U.S. targeting nanotechnology, targeted delivery, and formulation stability. JP2014114320 fits into this trajectory, emphasizing approach-specific claims that regulate critical process steps or physical characteristics influencing bioavailability.
Legal and Commercial Implications
Scope and enforceability depend heavily on the specificity of claims. Broad claims risk invalidation if prior art demonstrates similar methods, whereas narrowly tailored claims can provide robust protection against competitors. For drug developers, understanding claim limitations is vital for designing around patents or for infringement analysis.
The patent’s presence in a crowded landscape necessitates strategic positioning—either by demonstrating an inventive step over prior art or by leveraging complementary intellectual property (e.g., formulation patents) to create a protective portfolio.
Conclusion
JP2014114320 exemplifies strategic innovation in pharmaceutical formulations, focusing on manufacturing processes and composition modifications for enhanced bioavailability. Its scope extends across method and product claims, with an emphasis on process parameters and physical characteristics that influence therapeutic efficacy. While building upon a competitive landscape of nanotechnology and lipid-based delivery systems, this patent consolidates Japanese inventiveness in improving oral drug absorption.
Pharmaceutical entities should consider the patent’s specific claims when developing bioavailability enhancement technologies, as infringement could arise through similar processing steps or formulations. Conversely, opportunities exist to design around these claims by altering process parameters or formulation components not encompassed within the patent’s scope.
Key Takeaways
- The patent claims a comprehensive approach combining process steps and composition features to improve drug bioavailability.
- Its scope includes method claims for manufacturing processes and composition claims for drug formulations with specific physicochemical traits.
- The patent landscape in Japan reflects active innovation in nanotechnology, lipid-based systems, and physical modification techniques aimed at enhancing drug absorption.
- Strategic patenting in this space involves balancing broad claim coverage with detailed limitations to ensure enforceability.
- Companies should carefully analyze such patents when developing new formulations to avoid infringement and identify opportunities for creative design-around strategies.
FAQs
1. Does JP2014114320 cover all bioavailability-enhancing formulations?
No. Its claims are specific to particular processing methods and physical characteristics; alternative approaches outside these parameters may not infringe.
2. Can this patent be enforced against competitors?
Yes, if a competitor employs similar manufacturing steps or formulations falling within the scope of the claims, enforcement could be pursued.
3. How does this patent differ from similar formulations in the US or EU?
Differences may lie in claim language, scope, and specific process steps; international patent families aim to synchronize protection but often include jurisdiction-specific nuances.
4. What are potential design-around strategies?
Altering process parameters, using different excipients, or changing physical characteristics not claimed could circumvent this patent.
5. What is the importance of physical form claims in this patent?
Physical form claims (e.g., amorphous versus crystalline) are critical because they directly influence bioavailability and can serve as differentiating features over prior art.
References
[1] Patent JP2014114320 “Method for Producing a Pharmaceutical Composition with Enhanced Bioavailability,” Japan Patent Office, 2014.
